• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黄斑部玻璃膜疣、色素改变及渗出性改变与年龄相关性黄斑变性的关系。一项对1000名老年人的流行病学研究。

Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration. An epidemiological study of 1000 aged individuals.

作者信息

Vinding T

机构信息

University Eye Clinic, Rigshospitalet, Copenhagen, Denmark.

出版信息

Acta Ophthalmol (Copenh). 1990 Aug;68(4):410-4. doi: 10.1111/j.1755-3768.1990.tb01668.x.

DOI:10.1111/j.1755-3768.1990.tb01668.x
PMID:2220356
Abstract

Macular changes in 60 to 80-year-old people i.e. drusen (DR), pigmentary changes (PC) and exudative changes (EXC) are assessed by fundoscopy in a random and age stratified population with 924 of the participants examined in both maculae (1848 eyes). DR, PC and EXC were found in 18.4%, 12.9% and 2.1% of all eyes with a rising frequency associated with increasing age. A separation was made between changes implying a visual acuity of 6/9 or less as criteria of age-related macular degeneration (AMD) and age related macular changes without visual impairment (AMCW). The occurrence of DR, PC and EXC from eyes with AMD showed an age related rise which was also found for DR, contrary to PC and EXC deriving from eyes with AMCW. The basic forms of AMD, atrophic and exudative, were represented in 78.6% and 21.4% of individuals or 80.9% and 19.1% of eyes with AMD. The predominant findings in AMD eyes were DR + PC in combination represented in 60.7% of atrophic and 66.8% of exudative AMD eyes, while in atrophic AMCW eyes DR as only finding was leading with 59.2%. It is concluded that in eyes with atrophic macular changes, DR, respectively PC as only finding involves no visual deterioration in 80.6%, respectively 72.6%, while DR + PC in combination, as well as the appearance of EXC, are found to be the most likely expression of AMD as long as a visual impairment of 6/9 or worse is included in the definition of AMD.

摘要

在一个随机且按年龄分层的60至80岁人群中,通过检眼镜检查评估黄斑变化,即玻璃膜疣(DR)、色素变化(PC)和渗出性变化(EXC),924名参与者的双眼均接受了检查(共1848只眼)。在所有眼中,DR、PC和EXC的发现率分别为18.4%、12.9%和2.1%,且频率随年龄增长而上升。根据年龄相关性黄斑变性(AMD)的标准,即视力为6/9或更低,以及无视力损害的年龄相关性黄斑变化(AMCW),对这些变化进行了区分。AMD眼中DR、PC和EXC的发生率呈现与年龄相关的上升趋势,DR也是如此,这与AMCW眼中的PC和EXC情况相反。AMD的基本形式,萎缩性和渗出性,在AMD个体中分别占78.6%和21.4%,或在AMD眼中分别占80.9%和19.1%。AMD眼中的主要发现是DR + PC联合出现,在萎缩性AMD眼中占60.7%,在渗出性AMD眼中占66.8%,而在萎缩性AMCW眼中,仅DR作为发现结果占主导地位(59.2%)。得出的结论是,在萎缩性黄斑变化的眼中,仅发现DR或PC分别在80.6%和72.6%的情况下不会导致视力下降,而只要将视力损害为6/9或更差纳入AMD的定义中,DR + PC联合出现以及EXC的出现被认为是AMD最可能的表现形式。

相似文献

1
Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration. An epidemiological study of 1000 aged individuals.黄斑部玻璃膜疣、色素改变及渗出性改变与年龄相关性黄斑变性的关系。一项对1000名老年人的流行病学研究。
Acta Ophthalmol (Copenh). 1990 Aug;68(4):410-4. doi: 10.1111/j.1755-3768.1990.tb01668.x.
2
Visual impairment of age-related macular degeneration. An epidemiological study of 1000 aged individuals.年龄相关性黄斑变性的视力损害。对1000名老年人的流行病学研究。
Acta Ophthalmol (Copenh). 1990 Apr;68(2):162-7. doi: 10.1111/j.1755-3768.1990.tb01898.x.
3
Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort.存在黄斑玻璃膜疣或色素沉着的眼睛发生年龄相关性黄斑变性的风险:蓝山眼研究队列
Arch Ophthalmol. 2003 May;121(5):658-63. doi: 10.1001/archopht.121.5.658.
4
Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study.年龄相关性黄斑变性的15年累积发病率:比弗迪尔姆眼科研究
Ophthalmology. 2007 Feb;114(2):253-62. doi: 10.1016/j.ophtha.2006.10.040.
5
14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study.年龄相关性黄斑病变的14年发病率、进展及视觉损害:哥本哈根市眼科研究
Ophthalmology. 2005 May;112(5):787-98. doi: 10.1016/j.ophtha.2004.11.040.
6
Age-related macular degeneration. Macular changes, prevalence and sex ratio. An epidemiological study of 1000 aged individuals.年龄相关性黄斑变性。黄斑变化、患病率及性别比。对1000名老年人的流行病学研究。
Acta Ophthalmol (Copenh). 1989 Dec;67(6):609-16. doi: 10.1111/j.1755-3768.1989.tb04392.x.
7
[Age-related Macular Degeneration in the Japanese].[日本的年龄相关性黄斑变性]
Nippon Ganka Gakkai Zasshi. 2016 Mar;120(3):163-88; discussion 189.
8
The time pattern of bilateral exudative age-related macular degeneration.双侧渗出性年龄相关性黄斑变性的时间模式。
Acta Ophthalmol Scand. 2005 Jun;83(3):333-6. doi: 10.1111/j.1600-0420.2005.00451.x.
9
The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.年龄相关性黄斑病变的五年发病率和进展情况:比弗迪姆眼研究
Ophthalmology. 1997 Jan;104(1):7-21. doi: 10.1016/s0161-6420(97)30368-6.
10
[Prevalence study of age-related macular degeneration in Caojiadu blocks, Shanghai].[上海曹家渡社区年龄相关性黄斑变性患病率研究]
Zhonghua Yan Ke Za Zhi. 2005 Jan;41(1):15-9.

引用本文的文献

1
Aqueous humor cytokine levels in patients with subretinal fibrosis in neovascular age-related macular degeneration.新生血管性年龄相关性黄斑变性伴视网膜下纤维化患者房水中细胞因子水平。
BMC Ophthalmol. 2024 Aug 12;24(1):335. doi: 10.1186/s12886-024-03614-3.
2
Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study.抗 FGF2 单克隆抗体 Umedaptanib 聚乙二醇眼部注射治疗新生血管性年龄相关性黄斑变性(nAMD)的安全性和耐受性:一项 1 期、开放标签研究。
Eye (Lond). 2024 Apr;38(6):1149-1154. doi: 10.1038/s41433-023-02849-6. Epub 2023 Dec 1.
3
Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients.
抗 FGF2 治疗在渗出性年龄相关性黄斑变性(nAMD)中的临床概念验证:治疗初治和抗 VEGF 预处理患者的 2 期试验。
Eye (Lond). 2024 Apr;38(6):1140-1148. doi: 10.1038/s41433-023-02848-7. Epub 2023 Nov 30.
4
Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.RBM-007,一种抗 FGF2 适体的多种治疗应用。
Cells. 2021 Jun 28;10(7):1617. doi: 10.3390/cells10071617.
5
Selective age-related changes in orientation perception.选择性与年龄相关的方向知觉变化。
J Vis. 2020 Dec 2;20(13):13. doi: 10.1167/jov.20.13.13.
6
Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease.抗成纤维细胞生长因子2适体在视网膜疾病动物模型中的抗血管生成和抗瘢痕双重作用
Mol Ther Nucleic Acids. 2019 Sep 6;17:819-828. doi: 10.1016/j.omtn.2019.07.018. Epub 2019 Aug 1.
7
Angiotensin II-related hypertension and eye diseases.血管紧张素II相关高血压与眼部疾病。
World J Cardiol. 2014 Sep 26;6(9):968-84. doi: 10.4330/wjc.v6.i9.968.
8
Age-related macular degeneration and changes in the extracellular matrix.年龄相关性黄斑变性与细胞外基质的变化
Med Sci Monit. 2014 Jun 18;20:1003-16. doi: 10.12659/MSM.889887.
9
Durable recovery of the macular architecture and functionality of a diagnosed age-related macular degeneration 1 year after a single intravitreal injection of dobesilate.单次玻璃体内注射羟苯磺酸钙1年后,确诊的年龄相关性黄斑变性患者黄斑结构和功能的持久恢复。
BMJ Case Rep. 2013 Nov 13;2013:bcr2013010203. doi: 10.1136/bcr-2013-010203.
10
Intravitreal dobesilate in the treatment of choroidal neovascularisation associated with age-related macular degeneration: report of two cases.玻璃体内注射羟苯磺酸钙治疗年龄相关性黄斑变性伴脉络膜新生血管:两例报告
BMJ Case Rep. 2012 Sep 3;2012:bcr2012006619. doi: 10.1136/bcr-2012-006619.